Dupixent vs Otezla
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Dupixent | US Otezla | |
|---|---|---|
| Generic name | dupilumab | apremilast |
| Drug class | IL-4/IL-13 Inhibitor (Biologic) | PDE4 Inhibitor |
| Treats | Eczema, asthma, nasal polyps | Plaque psoriasis, psoriatic arthritis, Behçet's disease |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Sanofi/Regeneron | Amgen |
| Year approved | 2017 | 2014 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $390M | $110M |
| Common side effects | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia | Diarrhea, Nausea, Headache, Weight loss |
Frequently asked questions
Is Dupixent or Otezla better?
Neither is universally "better." Dupixent (dupilumab) and Otezla (apremilast) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dupixent and Otezla?
Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron, while Otezla is a PDE4 Inhibitor made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.